News about Clinical Trials

GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021

Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.

Clinical Trials | 16/04/2026 | By News Bureau |  374

Samsung Bioepis Starts Phase 1 Trial for Nectin-4 ADC SBE303

Samsung Bioepis launches Phase 1 trial of SBE303, a Nectin-4 targeting ADC, marking a key step in advancing its oncology pipeline and Antibody-Drug Conjugate development.

Clinical Trials | 16/04/2026 | By News Bureau |  129

GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers

GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.

Clinical Trials | 14/04/2026 | By News Bureau |  252

Hoth Therapeutics Reports Positive HT-VA CRADA Data

Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.

Clinical Trials | 14/04/2026 | By News Bureau |  301

Allogene Reports ALPHA3 Data: Cema-Cel Shows 58 Percent MRD Clearance in LBCL

Allogene reports ALPHA3 interim data showing 58 percent MRD clearance with cema-cel in LBCL, rapid ctDNA reduction and favourable safety profile with no serious adverse events.

Clinical Trials | 14/04/2026 | By News Bureau |  172

MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial

MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.

Clinical Trials | 13/04/2026 | By News Bureau |  143

Sparian Biosciences Begins Phase I Trial of Oral Pain Drug SBS-147 Targeting Opioid Alternatives

Sparian Biosciences advances SBS-147 into Phase I trials, aiming to develop a safer, non-opioid oral treatment for acute and chronic pain.

Clinical Trials | 11/04/2026 | By News Bureau |  258

Avacta Group doses first patient in AVA6103 trial, advances targeted cancer therapy platform

Phase I FOCUS-01 study to evaluate novel peptide-drug conjugate across four solid tumours following Euro 10 million fundraise and collaboration with Tempus AI.

Clinical Trials | 11/04/2026 | By News Bureau |  451

Boehringer Ingelheim and BioNTech Partners to Test Novel Immunotherapy Combo in Aggressive Lung Cancer

The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.

Clinical Trials | 11/04/2026 | By News Bureau |  178

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Clinical Trials | 09/04/2026 | By News Bureau |  274